Malignant lymphomas are lymphoproliferative disorders arising in both lymphoid tissue
and nonlymphoid organ systems. Treatment rarely is surgical and currently relies on
a combination of chemotherapy and radiation therapy. The role of imaging is to determine
the spread of the disease, to identify targets, and to assess the therapeutic response.
Imaging techniques mainly use morphological criteria and may underestimate infiltrative
disease, as observed in bones. The frequent presence of residual masses after treatment
usually prevents classification of patients as complete response. Over time, positron
emission tomography (PET) with F18-fluorodeosyglucose (FDG) has become a prominent
part of the work up at diagnosis and during follow-up. Recently, PET has been integrated
in the response criteria for malignant lymphoma.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Clinical ImagingAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
Article info
Identification
Copyright
© 2009 Published by Elsevier Inc.
